Chufeng Zhang
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Feiwei Heji Enhances Antitumor Immunity by MLL4-Dependent Regulation of Pyroptosis in Lung Cancer.
Journal: Cancer science
Published: January 06, 2026
Feiwei Mixture Exerts Antitumor Activity Against Non-Small Cell Lung Cancer via Regulating NR1D1-Mediated Immune Cell Infiltration.
Journal: Advanced biology
Published: September 29, 2025
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study.
Journal: Oncology letters
Published: November 20, 2023
Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
Journal: Journal of cancer research and clinical oncology
Published: August 02, 2023
Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: June 28, 2023
Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study.
Journal: Future oncology (London, England)
Published: July 13, 2021
Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Journal: Cancer science
Published: December 28, 2020
In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.
Journal: Thoracic cancer
Published: August 23, 2020
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: June 15, 2019
A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: November 21, 2018
Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Journal: Thoracic cancer
Published: August 28, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026